- 4-Methylimidazole
-
-
2026-07-03
- CAS:822-36-6
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200mt/year
- 4-Methylimidazole
-
-
2026-07-03
- CAS:822-36-6
- Min. Order: 25KG
- Purity: 98
- Supply Ability: 1MT
- 4-Methylimidazole
-
-
2026-07-03
- CAS:822-36-6
- Min. Order: 25Kg/Drum
- Purity: 98
- Supply Ability: 1MT
|
| | 4-Methylimidazole Basic information |
| | 4-Methylimidazole Chemical Properties |
| Melting point | 44-47 °C(lit.) | | Boiling point | 263 °C(lit.) | | density | 1.02 | | refractive index | 1.5037 | | Fp | >230 °F | | storage temp. | 2-8°C | | solubility | H2O: soluble, clear, colorless to yellow (50 mg/mL) | | form | Powder | | pka | pK1:7.55(＋1) (25°C) | | color | Reddish-brown to green to brown | | Water Solubility | Soluble in water. | | BRN | 1453 | | Henry's Law Constant | 2.4×100 mol/(m3Pa) at 25℃, HSDB (2015) | | Major Application | cleaning products
cosmetics
food and beverages
forensics and toxicology
personal care
veterinary | | InChI | 1S/C4H6N2/c1-4-2-5-3-6-4/h2-3H,1H3,(H,5,6) | | InChIKey | XLSZMDLNRCVEIJ-UHFFFAOYSA-N | | SMILES | Cc1c[nH]cn1 | | LogP | 0.230 | | CAS DataBase Reference | 822-36-6(CAS DataBase Reference) | | NIST Chemistry Reference | 4-Methylimidazole(822-36-6) | | IARC | 2B (Vol. 101) 2013 | | EPA Substance Registry System | 1H-Imidazole, 4-methyl- (822-36-6) |
| Hazard Codes | C | | Risk Statements | 21/22-34-22 | | Safety Statements | 26-36/37/39-45-25 | | RIDADR | UN 3263 8/PG 3 | | WGK Germany | 2 | | RTECS | NI7350000 | | TSCA | TSCA listed | | HazardClass | 8 | | PackingGroup | III | | HS Code | 29339900 | | Storage Class | 8A - Combustible corrosive hazardous materials | | Hazard Classifications | Acute Tox. 4 Dermal
Acute Tox. 4 Oral
Skin Corr. 1B | | Hazardous Substances Data | 822-36-6(Hazardous Substances Data) |
| | 4-Methylimidazole Usage And Synthesis |
| Chemical Properties | Slightly yellow chunks. soluble in water and ethanol. | | Uses | 4-Methylimidazole is a monomethylated imidazole that can be used as a building block in the preparation of a wide range of biologically active compounds. 4-Methylimidazole is a product which results f
rom the interaction of reducing sugars with ammonia. 4-Methylimidazole showed convulsant activity in animals and is listed as a possible carcinogen. | | Uses | 4-Methylimidazole is used for the curing agent of epoxy resin, the main raw material of medicine cimetidine. It can also be used for synthesis of antibacterial agent. | | Preparation | 4-Methylimidazole is synthesized by the reaction of glyoxal, acetaldehyde and ammonia. Another method to synthesize the compound is by catalytic dehydrogenation of imidazoline derivatives. 4-Methylimidazole may be synthesized from propanol and formamide, by catalytic cyclization of bisformamidipropane or by photolysis of alkenyltetrazole derived from alkenes by sequential epoxidation, ring opening and dehydration (NTP, 2007). | | Definition | ChEBI: 4-methylimidazole is imidazole substituted at position 4 by a methyl group. It has a role as a carcinogenic agent and a reaction intermediate. | | General Description | 4(5)-Methylimidazole was quantified in coffee by GC-MS method. | | Biological Activity | 4-Methylimidazole forms complexes with heme-containing enzymes such as cytochrome P450 (CYP) and leads to inhibition of mixed-function oxidase activity. 4-Methylimidazole has been reported to significantly inhibit CYP2E1 activity in rat liver and toluenesulfonylurea hydroxylase (CYP2C9) activity in human and rat microsomes. In addition, it stimulated phosphorylation of rabbit kidney (Na and K)-adenosine triphosphatase and exhibited significant antioxidant activity in a lipid peroxyl radical activity capture assay. | | Side effects | 4-Methylimidazole is an eye irritant, causes burns, may cause corrosive damage to the upper respiratory tract and lungs if inhaled, and is harmful if ingested.
In vivo findings: No histopathological changes were observed in 15-day oral studies in rats and mice. A 14-week oral study showed tremors, ataxia, anaemia, vacuolisation of hepatocytes and testicular degeneration in rats and anaemia, vacuolisation of hepatocytoplasm and renal degeneration in mice.
Histopathological liver changes were also observed in a 106-week oral study in rats, causing neurological effects including hyperexcitability, convulsions and seizures in livestock and experimental animals. Reproductive organ toxicity and reduced fertility were observed in male rats.
Evidence of carcinogenicity: no carcinogenicity in male rats; ambiguous in female rats; clear evidence in male and female mice; irritating or corrosive to rabbit skin. | | Purification Methods | Recrystallise 4-methylimidazole from *benzene or pet ether. It has m 56o after sublimation. The picrate has m 162-163.5o (from EtOH). [Beilstein 23 II 60, 23 III/IV 597, 23/5 V 89.] |
| | 4-Methylimidazole Preparation Products And Raw materials |
|